Search Records

The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will switch certain uses of Esomeprazole to nonprescription status for human use by modifying the Human Prescription Drug List (PDL).

The purpose of this Notice of Amendment is to announce the revised listing for hydrocortisone on the Prescription Drug List (PDL).

The purpose of this Notice of Amendment is to notify about the addition of hydroquinone or its derivatives to the Prescription Drug List (PDL) for human use when sold in concentrations greater than 2% in topical products.

The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing for levonorgestrel on the Prescription Drug List (PDL). Only the Human part of the PDL was revised; the listing for Veterinary use will remain unchanged.

The purpose of this Notice of Amendment is to announce the revised listing for lovastatin on the Prescription Drug List (PDL). As stated in the Notice of Intent to Amend, posted June 4, 2014, the revision will allow lovastatin to be marketed as a nonprescription product. Only the Human part of...

The purpose of this Notice of Amendment is to notify that Health Canada has revised the listing for Adrenocortical hormones on the Prescription Drug List (PDL) to allow the nonprescription use of Mometasone furoate for the conditions listed below. Only the Human part of the PDL was revised.

The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will switch certain uses of Polymyxin B to prescription status for veterinary use by adding it to the Veterinary Prescription Drug List (PDL).

The purpose of this Notice of Amendment is to announce the revised listing for Adrenocortical hormones to allow the nonprescription use of triamcinolone acetonide for the conditions listed below. Only the Human part of the PDL has been revised.

The updated screening criteria for Abbreviated New Drug Submissions (ANDS) and their supplements (SANDS) will help assess the completeness of the drug submission and identify significant deficiencies prior to the review process.

The Guidance Document: Fees for the Review of Drug Submissions and Applications has been updated. The Document Change Log has been revised to reflect the changes and other minor revisions.